This section provides information on the press release or notice to the public of a certain marketing authorization holder when a recall of their product is pursued. FDA Philippines posts the advisory of the company as a public service but does not endorse either the product or the company. For additional information on recalls, see https://www.fda.gov.ph/category/drugs-advisories/.
|DATE||PRODUCT DESCRIPTION||BRAND NAME||MAH||REASON FOR RECALL||ANNOUNCEMENT|
|02 December 2021||Losartan-containing products||-||Sandoz Philippines Corporation||Quality defect||View PDF|
|12 March 2021||Amoxicillin (as trihydrate) 125 mg/5 mL Powder for Suspension||Himox||UNILAB, Inc.||Misprinting of Labels||View PDF|
|01 March 2021||Cloxacillin (as sodium) 500mg capsule (Philclox)||Philclox||PhilRx Pharma Inc.||Out-of-Specification||View PDF|
|24 February 2021||Sertraline (as Hydrochloride) 50 mg Film-Coated Tablet||Serenata||Torrent Pharma Philippines, Inc.||Out-of-Specification||View PDF|
|08 January 2021||Ceftolozane + Tazobactam 1 g/500 mg Powder for Injection (IV)||Zerbaxa||Merck Sharp & Dohme (I.A.) LLC||Out-of-Specification||View PDF|